Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.71+0.10 (+0.26%)
Close on Nov 17, 2026Market cap $27.96BP/E –Yield –
Roivant Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Roivant Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $730.91M, up 25.4% year over year. For fiscal 2025 it was $681.81M, up 23.9% from the year before. The highest annual figure on record is $681.81M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | $681.81M | +23.9% |
| FY2024 | Mar 31, 2025 | $550.41M | +25.1% |
| FY2023 | Mar 31, 2024 | $439.91M | -3.1% |
| FY2022 | Mar 31, 2023 | $454.06M | -6.0% |
| FY2021 | Mar 31, 2022 | $483.04M | +104.1% |
| FY2020 | Mar 31, 2021 | $236.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | $202.02M | +32.1% |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | $198.95M | +37.0% |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | $165.38M | +16.8% |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | $164.57M | +15.0% |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | $152.92M | +26.9% |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | $145.24M | +35.0% |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | $141.60M | +30.9% |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | $143.07M | +24.6% |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | $120.51M | -3.7% |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | $107.56M | +77.2% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $108.15M | -13.8% |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | $114.79M | -13.0% |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | $125.13M | -7.9% |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $60.70M | -55.1% |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | $125.53M | -8.6% |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | $132.00M | -0.1% |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | $135.83M | +73.0% |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | $135.08M | -33.2% |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | $137.35M | +41.0% |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | $132.10M | +124.9% |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | $78.52M | – |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | $202.26M | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | $97.41M | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | $58.73M | – |
See a number that looks wrong?